Revenue Breakdown
Composition ()
No data
Revenue Streams
Pacific Biosciences of California Inc (PACB) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Consumable revenue, accounting for 55.4% of total sales, equivalent to $21.28M. Other significant revenue streams include Instrument revenue and Service And Other. Understanding this composition is critical for investors evaluating how PACB navigates market cycles within the Advanced Medical Equipment & Technology industry.
Profitability & Margins
Evaluating the bottom line, Pacific Biosciences of California Inc maintains a gross margin of 35.26%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -119.13%, while the net margin is -90.43%. These profitability ratios, combined with a Return on Equity (ROE) of -213.45%, provide a clear picture of how effectively PACB converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, PACB competes directly with industry leaders such as CERS and NPCE. With a market capitalization of $507.36M, it holds a leading position in the sector. When comparing efficiency, PACB's gross margin of 35.26% stands against CERS's 59.23% and NPCE's 77.39%. Such benchmarking helps identify whether Pacific Biosciences of California Inc is trading at a premium or discount relative to its financial performance.
